GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Selling, General, & Admin. Expense

Zenith Capital (Zenith Capital) Selling, General, & Admin. Expense : $ Mil (TTM As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Zenith Capital's selling, general, & admin. expense for the three months ended in . 20 was $0.00 Mil. Zenith Capital does not have enough years/quarters to calculate its selling, general, & admin. expense for the trailing twelve months (TTM) ended in . 20.


Zenith Capital Selling, General, & Admin. Expense Historical Data

The historical data trend for Zenith Capital's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Selling, General, & Admin. Expense Chart

Zenith Capital Annual Data
Trend
Selling, General, & Admin. Expense

Zenith Capital Quarterly Data
Selling, General, & Admin. Expense

Competitive Comparison of Zenith Capital's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Zenith Capital's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenith Capital's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Selling, General, & Admin. Expense falls into.



Zenith Capital Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.


Zenith Capital  (OTCPK:ZHCLF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Zenith Capital Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (Zenith Capital) Business Description

Industry
Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines